Subcellular Localization Dictates Therapeutic Function: Spatially Targeted Delivery of Amuc_1100 by Engineered Lacticaseibacillus paracasei L9 Enhances Intestinal Barrier in Colitis
Nutrients · 2025
DOI: 10.3390/nu18010123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Xinrui Dong und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China. Hauptthemen laut MEDLINE: Colitis, Probiotics, Lacticaseibacillus paracasei, Bacterial Outer Membrane Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, 111 Project from the Education Ministry of China, 2115 Talent Development Program of China Agricultural University.
Abstract (Originalsprache)
Background/Objectives: Impaired intestinal barrier function is a hallmark of inflammatory bowel disease (IBD). Akkermansia muciniphila and its outer membrane protein Amuc_1100 can enhance this barrier, but the clinical application of Amuc_1100 is limited by the fastidious growth of its native host. This study aimed to overcome this by utilizing the robust probiotic Lacticaseibacillus paracasei L9 for targeted Amuc_1100 delivery.
Methods
We engineered Lc. paracasei L9 to express Amuc_1100 via intracellular (pA-L9), secretory (pUA-L9), and surface-display (pUPA-L9) strategies. Their efficacy was assessed in Lipopolysaccharide (LPS)-induced macrophages and a dextran sulfate sodium (DSS)-induced colitis mouse model, evaluating inflammation, barrier integrity, and mucosal repair.
Results
The secretory (pUA-L9) and surface-display (pUPA-L9) strains most effectively suppressed pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) in macrophages. In mice, both strains alleviated colitis and outperformed native A. muciniphila in improving disease activity. Crucially, they exhibited distinct, specialized functions: pUA-L9 acted as a systemic immunomodulator, reducing pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α), elevating anti-inflammatory mediators (IL-4 and IL-10), and promoting goblet cell differentiation; notably, the inhibitory effect of pUA-L9 on IL-6 expression was approximately 2-fold greater than that of pUPA-L9. In contrast, pUPA-L9 excelled in local barrier repair, uniquely restoring mucus layer integrity (Muc1, Muc2, and Tff3) and reinforcing tight junctions (ZO-1, Occludin, Claudin1, Claudin3, and Claudin4). In particular, pUPA-L9 increased Muc2 expression by approximately 3.6-fold compared with pUA-L9.
Conclusions
We demonstrate that the subcellular localization of Amuc_1100 within an engineered probiotic dictates its therapeutic mode of action. The complementary effects of secretory and surface-displayed Amuc_1100 offer a novel, spatially targeted strategy for precision microbiome therapy in IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China.
- Key Laboratory of Functional Dairy, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
- School of Food and Health, Beijing Technology and Business University, Beijing 100048, China.
- Research Center for Probiotics, China Agricultural University, Beijing 101299, China.
- Shanghai Engineering Research Center of Food Microbiology, School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China.
- School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 200240, China.
ORCID-Profile: Zhengyuan Zhai, Ming Zhang, Hao Zhang, Liang Zhao
Förderung
- National Key Research and Development Program of China
- 111 Project from the Education Ministry of China
- 2115 Talent Development Program of China Agricultural University
Zitieren
APA
Dong, X., Lin, L., Miao, W., Zhai, Z., Hao, Y., Zhang, M., Wang, R., Ge, S., Zhang, H., Ai, L., & Zhao, L. (2025). Subcellular Localization Dictates Therapeutic Function: Spatially Targeted Delivery of Amuc_1100 by Engineered Lacticaseibacillus paracasei L9 Enhances Intestinal Barrier in Colitis. Nutrients. https://doi.org/10.3390/nu18010123
Vancouver
Dong X, Lin L, Miao W, Zhai Z, Hao Y, Zhang M, et al. Subcellular Localization Dictates Therapeutic Function: Spatially Targeted Delivery of Amuc_1100 by Engineered Lacticaseibacillus paracasei L9 Enhances Intestinal Barrier in Colitis. Nutrients. 2025. doi:10.3390/nu18010123
BibTeX
@article{Dong2025,
author = {Dong, Xinrui and Lin, Li and Miao, Weina and Zhai, Zhengyuan and Hao, Yanling and Zhang, Ming and Wang, Ran and Ge, Shaoyang and Zhang, Hao and Ai, Lianzhong and Zhao, Liang},
title = {Subcellular Localization Dictates Therapeutic Function: Spatially Targeted Delivery of Amuc_1100 by Engineered Lacticaseibacillus paracasei L9 Enhances Intestinal Barrier in Colitis},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu18010123}
}
EUVIMED